Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen

Biochemical and Biophysical Research Communications

Volumn 387, Issue 4, 2009, Pages 748-753

  Blanquart, Christophe ^a,b   Karouri, Salah Eddine ^a,b   Issad, Tarik ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

Breast cancer; ERK; PTP1B; Tamoxifen resistance; TC PTP

Indexed keywords

4 HYDROXYTAMOXIFEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PROTEIN TYROSINE PHOSPHATASE 1B; SMALL INTERFERING RNA; STAT3 PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RESISTANCE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RNA, SMALL INTERFERING; TAMOXIFEN;

EID: 68549126713     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.105     Document Type: Article

References (17)

1. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7 (2006) 833-846
2. Ostman A., Hellberg C., and Bohmer F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6 (2006) 307-320
3. Dube N., Cheng A., and Tremblay M.L. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. USA 101 (2004) 1834-1839
4. Wiener J.R., Hurteau J.A., Kerns B.J., Whitaker R.S., Conaway M.R., Berchuck A., and Bast Jr. R.C. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am. J. Obstet. Gynecol. 170 (1994) 1177-1183
5. Wiener J.R., Kerns B.J., Harvey E.L., Conaway M.R., Iglehart J.D., Berchuck A., and Bast Jr. R.C. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J. Natl. Cancer Inst. 86 (1994) 372-378
6. Nanney L.B., Davidson M.K., Gates R.E., Kano M., and King Jr. L.E. Altered distribution and expression of protein tyrosine phosphatases in normal human skin as compared to squamous cell carcinomas. J. Cutan. Pathol. 24 (1997) 521-532
7. Julien S.G., Dube N., Read M., Penney J., Paquet M., Han Y., Kennedy B.P., Muller W.J., and Tremblay M.L. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 39 (2007) 338-346
8. Bentires-Alj M., and Neel B.G. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67 (2007) 2420-2424
9. Arias-Romero L.E., Saha S., Villamar-Cruz O., Yip S.C., Ethier S.P., Zhang Z.Y., and Chernoff J. Activation of Src by protein tyrosine phosphatase 1B is required for ErbB2 transformation of human breast epithelial cells. Cancer Res. 69 (2009) 4582-4588
10. Boute N., Boubekeur S., Lacasa D., and Issad T. Dynamics of the interaction between the insulin receptor and protein tyrosine-phosphatase 1B in living cells. EMBO Rep. 4 (2003) 313-319
11. Liu J.F., Issad T., Chevet E., Ledoux D., Courty J., Caruelle J.P., Barritault D., Crepin M., and Bertin B. Fibroblast growth factor-2 has opposite effects on human breast cancer MCF-7 cell growth depending on the activation level of the mitogen-activated protein kinase pathway. Eur. J. Biochem. 258 (1998) 271-276
12. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., Eweis I., Wloch M., Livingston S., Seijo E., Cantor A., Lee J.H., Beam C.A., Sullivan D., Jove R., and Muro-Cacho C.A. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res. 12 (2006) 20-28
13. Gee J.M., Robertson J.F., Ellis I.O., and Nicholson R.I. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95 (2001) 247-254
14. Ibarra-Sanchez M.J., Wagner J., Ong M.T., Lampron C., and Tremblay M.L. Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappaB activation. Oncogene 20 (2001) 4728-4739
15. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., and Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68 (2008) 826-833
16. Gariboldi M.B., Ravizza R., Molteni R., Osella D., Gabano E., and Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 258 (2007) 181-188
17. Real P.J., Sierra A., De Juan A., Segovia J.C., Lopez-Vega J.M., and Fernandez-Luna J.L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21 (2002) 7611-7618